Simlukafusp Alfa ELISA Kit
- Catalog number: EL10134
- Availability: In Stock
$1,126.00
- Ex Tax: $1,126.00
- Stability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
- Detection method: Colorimetric
- Sample type: Plasma, Serum
- Assay type: Quantitative
- Sensitivity: 0.156 μg/ml
- Range: 0.31-5 μg/mL
- Recovery: 80-120%
- Background: Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein 伪 (FAP) and an IL-2 variant with a retained affinity for IL-2R尾纬 > IL-2 R尾纬 and abolished binding to IL-2 R伪. Here, we investigated the immunostimulatory properties of FAP-IL2v and its combination with programmed cell death protein 1 (PD-1) checkpoint inhibition, CD40 agonism, T cell bispecific and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. The binding and immunostimulatory properties of FAP-IL2v were investigated in vitro and compared with FAP-IL2wt. Tumor targeting was investigated in tumor-bearing mice and in a rhesus monkey. The ability of FAP-IL2v to potentiate the efficacy of different immunotherapies was investigated in different xenograft and syngeneic murine tumor models. FAP-IL2v bound IL-2 R尾纬 and FAP with high affinity in vitro, inducing dose-dependent proliferation of natural killer (NK) cells and CD4+/CD8+ T cells while being significantly less potent than FAP-IL2wt in activating immunosuppressive regulatory T cells (Tregs). T cells activated by FAP-IL2v were less sensitive to Fas-mediated apoptosis than those activated by FAP-IL2wt. Imaging studies demonstrated improved tumor targeting of FAP-IL2v compared to FAP-IL2wt. Furthermore, FAP-IL2v significantly enhanced the in vitro and in vivo activity of therapeutic antibodies that mediate antibody-dependent or T cell-dependent cellular cytotoxicity (TDCC) and of programmed death-ligand 1 (PD-L1) checkpoint inhibition. The triple combination of FAP-IL2v with an anti-PD-L1 antibody and an agonistic CD40 antibody was most efficacious. These data indicate that FAP-IL2v is a potent immunocytokine that potentiates the efficacy of different T- and NK-cell-based cancer immunotherapies.
- Alternative Names: FAP-IL2v, RO6874281/RG7461
- Shipping: 2-8 ℃
- Specifications: Simlukafusp Alfa
- Note: For Research Use Only.
Image Data
No validation image data is currently available for this product.
Datasheet
